


FORM PTO-1390 (REV 11-98)		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		ATTORNEY'S DOCKET NUMBER 1303-110	
TRANSMITTAL LETTER TO THE UNITED STATES DESIGNATED/ELECTED OFFICE (DO/EO/US) CONCERNING A FILING UNDER 35 U.S.C. 371				U.S. APPLICATION NO. (If known, see 37 C.F.R. 1.5) 09/674853 (To Be Assigned)	
INTERNATIONAL APPLICATION NO. PCT/EP99/03075		INTERNATIONAL FILING DATE 5 May 1999		PRIORITY DATE CLAIMED 8 May 1998	
TITLE OF INVENTION GENETICALLY-MODIFIED FIBROBLASTS AND THE USE THEREOF					
APPLICANT(S) FOR DO/EO/US MAVILIO					
Applicant herewith submits to the United States Designated/Elected Office (DO/EO/US) the following items and other information:					
1. <input checked="" type="checkbox"/> This is a FIRST submission of items concerning a filing under 35 U.S.C. 371.					
2. <input type="checkbox"/> This is a SECOND or SUBSEQUENT submission of items concerning a filing under 35 U.S.C. 371.					
3. <input checked="" type="checkbox"/> This is an express request to begin national examination procedures (35 U.S.C. 371(f) at any time rather than delay examination until the expiration of the applicable time limit set in 35 U.S.C. 371(b) and PCT Articles 22 and 39(1).					
4. <input checked="" type="checkbox"/> A proper Demand for International Preliminary Examination was made by the 19 th month from the earliest claimed priority date.					
5. A copy of the International Application as filed (35 U.S.C. 371(c)(2)).					
6. <input type="checkbox"/> is transmitted herewith (required only if not transmitted by the International Bureau).					
7. <input checked="" type="checkbox"/> has been transmitted by the International Bureau.					
8. <input type="checkbox"/> is not required, as the application was filed in the United States Receiving Office (RO/US).					
9. <input type="checkbox"/> A translation of the International Application into English (35 U.S.C. 371(c)(2)).					
10. <input checked="" type="checkbox"/> Amendments to the claims of the International Application under PCT Article 19 (35 U.S.C. 371(c)(3)).					
11. <input type="checkbox"/> are transmitted herewith (required only if not transmitted by the International Bureau).					
12. <input checked="" type="checkbox"/> have been transmitted by the International Bureau.					
13. <input type="checkbox"/> have not been made; however, the time limit for making such amendments has NOT expired.					
14. <input type="checkbox"/> have not been made and will not be made.					
15. <input type="checkbox"/> A translation of the amendments to the claims under PCT Article 19 (U.S.C. 371(c)(3)).					
16. <input checked="" type="checkbox"/> An oath or declaration of the inventor(s) (35 U.S.C. 371(c)(4)).					
17. <input type="checkbox"/> A translation of the annexes to the International Preliminary Examination Report under PCT Article 36 (35 U.S.C. 371(c)(5)).					
Items 11. To 16. Below concern document(s) or information included:					
11. <input type="checkbox"/> An Information Disclosure Statement under 37 C.F.R. 1.97 and 1.98.					
12. <input checked="" type="checkbox"/> An assignment document for recording. A separate cover sheet in compliance with 37 C.F.R. 3.28 and 3.31 is included.					
13. <input checked="" type="checkbox"/> A FIRST preliminary amendment.					
14. <input type="checkbox"/> A SECOND or SUBSEQUENT preliminary amendment.					
15. <input type="checkbox"/> A substitute specification.					
16. <input type="checkbox"/> A change of power of attorney and/or address letter.					
17. <input checked="" type="checkbox"/> Other items or information. Verified Statement Claiming Small Entity Status - Independent Inventor & Small business Concern/ PTO-1449/ International Search Report					

U.S. APPLICATION NO. (If known, see 37 C.F.R. 1.5) 087674853		INTERNATIONAL APPLICATION NO. PCT/EP99/03075		ATTORNEY'S DOCKET NUMBER 1303-110	
17. <input checked="" type="checkbox"/> The following fees are submitted:				CALCULATIONS PTO USE ONLY	
BASIC NATIONAL FEE (37 C.F.R. 1.492(a)(1)-(5)): -- Neither international preliminary examination fee (37 C.F.R. 1.482) nor international search fee (37 C.F.R. 1.445(a)(2)) paid to USPTO and International Search Report not prepared by the EPO or JPO\$1000.00 -- International preliminary examination fee (37 C.F.R. 1.482) not paid to USPTO but International Search Report prepared by the EPO or JPO.....\$860.00 -- International preliminary examination fee (37 C.F.R. 1.482) not paid to USPTO but international search fee (37 C.F.R. 1.445(a)(2)) paid to USPTO\$710.00 -- International preliminary examination fee paid to USPTO (37 C.F.R. 1.482) but all claims did not satisfy provisions of PCT Article 33(1)-(4).....\$690.00 -- International preliminary examination fee paid to USPTO (37 C.F.R. 1.482) and all claims satisfied provisions of PCT Article 33(1)-(4).....\$100.00 <div style="text-align: right;">ENTER APPROPRIATE BASIC FEE AMOUNT =</div>				<div style="border: 1px solid black; padding: 2px;">\$ 860.00</div>	
Surcharge of \$130.00 for furnishing the oath or declaration later than <input type="checkbox"/> 20 <input type="checkbox"/> 30 months from the earliest claimed priority date (37 C.F.R. 1.492(e)).				<div style="border: 1px solid black; padding: 2px;">\$ 0.00</div>	
CLAIMS	NUMBER FILED	NUMBER EXTRA	RATE		
Total Claims	10	-20 = 0	X \$18.00	\$ 0.00	
Independent Claims	1	-3 = 0	X \$80.00	\$ 0.00	
MULTIPLE DEPENDENT CLAIMS(S) (if applicable)			\$270.00	\$ 0.00	
TOTAL OF ABOVE CALCULATIONS =				\$ 860.00	
Reduction by 1/2 for filing by small entity, if applicable. A Small Entity Statement must also be filed (Note 37 C.F.R. 1.9, 1.27, 1.28).				430.00	
SUBTOTAL =				\$ 430.00	
Processing fee of \$130.00, for furnishing the English Translation later than <input type="checkbox"/> 20 <input type="checkbox"/> 30 months from the earliest claimed priority date (37 C.F.R. 1.492(f)).				0.00	
TOTAL NATIONAL FEE =				\$ 430.00	
Fee for recording the enclosed assignment (37 C.F.R. 1.21(h)). The assignment must be accompanied by an appropriate cover sheet (37 C.F.R. 3.28, 3.31). \$40.00 per property +				40.00	
Fee for Petition to Revive Unintentionally Abandoned Application (\$1240.00 - Small Entity = \$620.00)				0.00	
TOTAL FEES ENCLOSED =				\$ 470.00	
				Amount to be: refunded \$	
				Charged \$	
<input checked="" type="checkbox"/> A check in the amount of \$900.00 to cover the above fees is enclosed. <input type="checkbox"/> Please charge my Deposit Account No. 14-1140 in the amount of \$_____ to cover the above fees. A duplicate copy of this form is enclosed. <input checked="" type="checkbox"/> The Commissioner is hereby authorized to charge any additional fees which may be required, or credit any overpayment to Deposit Account No. 14-1140. A duplicate copy of this form is enclosed. d. <input type="checkbox"/> The entire content of the foreign application(s), referred to in this application is/are hereby incorporated by reference in this application.					
NOTE: Where an appropriate time limit under 37 C.F.R. 1.494 or 1.495 has not been met, a petition to revive (37 C.F.R. 1.137(a) or (b)) must be filed and granted to restore the application to pending status.					
SEND ALL CORRESPONDENCE TO: NIXON & VANDERHYE P.C. 1100 North Glebe Road, 8 th Floor Arlington, Virginia 22201 Telephone: (703) 816-4000					
				 SIGNATURE	
				Arthur R. Crawford NAME	
				25,327 REGISTRATION NUMBER	
				November 7, 2000 Date	

8651V

Applicant or Patentee: _____ Attorney's Dkt. No. _____
Serial or Patent No.: _____
Filed or Issued: _____
For: _____

**VERIFIED STATEMENT (DECLARATION) CLAIMING SMALL ENTITY
STATUS [37 19(f) and 1.27(c)] - INDEPENDENT INVENTOR**

As a below named inventor, I hereby declare that I qualify as an independent inventor as defined in 37 CFR 1.9(c) for purposes of paying reduced fees under Section 41 (a) and (b) of Title 35, United States Code, to the Patent and Trademark Office with regard to the invention entitled:

Genetically-modified fibroblasts and the use thereof

described in

- ☐ the specification filed herewith.
☐ application Serial No. _____, filed _____
☐ patent No. _____, issued _____

I have not assigned, granted, conveyed or licensed and am under no obligation under contract or law to assign, grant, convey or license, any rights in the invention to any person who could not be classified as an independent inventor under 37 CFR 1.9(c) if that person had made the invention, or to any concern which would not qualify as a small business concern under 37 CFR 1.9(d) or a nonprofit organization under 37 CFR 1.9(e).

Each person, concern or organization to which I have assigned, granted, conveyed, or licensed or am under an obligation under contract or law to assign, grant, convey, or license any rights in the invention is listed below:

- ☐ no such person, concern, or organization
☐ persons, concerns or organizations listed below*

NOTE: Separate verified statements are required from each named person, concern or organization having rights to the invention averring to their status as small entities. (37 CFR 1.27)

Name _____
Address _____
☐ Individual ☐ Small Business Concern ☐ Nonprofit Organization

Name _____
Address _____
☐ Individual ☐ Small Business Concern ☐ Nonprofit Organization

Name _____
Address _____
☐ Individual ☐ Small Business Concern ☐ Nonprofit Organization

I acknowledge the duty to file, in this application of patent, notification of any change in status resulting in loss of entitlement to small entity status prior to paying, or at the time of paying, the earliest of the issue fee or any maintenance fee due after the date on which status as a small entity is no longer appropriate. [37 CFR 1.28(b)]

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under § 1001 of Title 18 of the United States Code, and that such willful false statements may jeopardize the validity of the application, any patent issuing thereon, or any patent to which this verified statement is directed.

MAVILIO Fulvio

NAME OF INVENTOR

NAME OF INVENTOR

NAME OF INVENTOR

Signature

Signature

Signature

13-10-2000

DATE

DATE

DATE

Applicant or Patentee: _____ Attorney's Dkt. No. _____
 Serial or Patent No.: _____
 Filed or Issued: _____
 For: _____

**VERIFIED STATEMENT (DECLARATION) CLAIMING SMALL ENTITY
 STATUS [37 19(f) and 1.27(c)] - SMALL BUSINESS CONCERN**

I hereby declare that I am

- ☐ the owner of the small business concern identified below:
☐ an official of the small business concern empowered to act on behalf of the concern identified below:
 NAME OF CONCERN GENERA S.p.A.
 ADDRESS OF CONCERN Via Olgettina, 58
MILANO, Italy

I hereby declare that the above identified small business concern qualifies as a small business concern as defined in 13 CFR 121.3-18, and reproduced in 37 CFR 1.9(d), for purposes of paying reduced fees under section 41(a) and (b) of Title 35, United States Code, in that the number of employees of the concern, including those of its affiliates, does not exceed 500 persons. For purposes of this statement (1) the number of employees of the business concern is the average over the previous fiscal year of the concern of the persons employed on a full-time, part-time or temporary basis during each of the pay periods of the fiscal year, and (2) concerns are affiliates of each other when either, directly or indirectly, one concern controls or has the power to control the other, or a third party or parties controls or has the power to control both.

I hereby declare that rights under contract or law have been conveyed to and remain with the small business concern identified above with regard to the invention, entitled:

Genetically-modified fibroblasts and the use thereof

by inventors _____ described in

- ☐ the specification filed herewith.
☐ application Serial No. _____, filed _____
☐ patent No. _____, issued _____

If the rights held by the above-identified small business concern are not exclusive, each individual, concern or organization having rights to the invention is listed below* and no rights to the invention are held by any person, other than the inventor who could not qualify as an independent inventor under 37 CFR 1.9(c) if that person made the invention, or by any concern which would not qualify as a small business concern under 37 CFR 1.9(d), or a nonprofit organization under 37 CFR 1.9(e). *NOTE: Separate verified statements are required from each named person, concern or organization having rights to the invention averring to their status as small entities (37 CFR 1.27)

Name _____
 Address _____
☐ Individual ☐ Small Business Concern ☐ Nonprofit Organization

Name _____
 Address _____
☐ Individual ☐ Small Business Concern ☐ Nonprofit Organization

I acknowledge the duty to file, in this application of patent, notification of any change in status resulting in loss of entitlement to small entity status prior to paying, or at the time of paying, the earliest of the issue fee or any maintenance fee due after the date on which status as a small entity is no longer appropriate. [37 CFR 1.28(b)]

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under § 1001 of Title 18 of the United States Code, and that such willful false statements may jeopardize the validity of the application, any patent issuing thereon, or any patent to which this verified statement is directed.

NAME OF PERSON SIGNING Filippo Bettini
 TITLE OF PERSON OTHER THAN OWNER _____
 ADDRESS OF PERSON SIGNING Via Olgettina, 58 - Milano, Italy
 SIGNATURE F. Bettini DATE 13.10.2000

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of

MAVILIO

Atty. Ref.: 1303-110

Serial No. (To Be Assigned)

Group:

National Phase of PCT/EP99/03075

Filed: November 7, 2000

Examiner:

For: **GENETICALLY-MODIFIED FIBROBLASTS AND THE
USE THEREOF**

* * * * *

November 7, 2000

Assistant Commissioner for Patents
Washington, DC 20231
Sir:

PRELIMINARY AMENDMENT

Prior to calculation of the filing fee and in order to place the above identified application in better condition for examination, please amend the claims as follows:

IN THE CLAIMS

Claim 9, lines 1-2, change "claims 1-8" to --claim 1--.


REMARKS

The above amendments are made to place the claims in a more traditional format.

Respectfully submitted,

NIXON & VANDERHYE P.C.

By:



Arthur R. Crawford

Reg. No. 25,327

ARC:ms

1100 North Glebe Road, 8th Floor
Arlington, VA 22201-4714
Telephone: (703) 816-4000
Facsimile: (703) 816-4100

GENETICALLY-MODIFIED FIBROBLASTS AND THE USE
THEREOF

The present invention relates to an ex-vivo method for the myogenic conversion of genetically-modified fibroblasts, for use in the correction of congenital defects of the muscular system, such as primary monogenic myopathies, or in the production of therapeutical proteins.

5 Furthermore, the invention relates to the use of genetically-modified fibroblasts for the preparation of compositions for cell implants for the treatment of muscle pathologies with a genetic aetiology, or for the in vivo secretion of recombinant proteins of therapeutical importance. In particular, the invention is valuable for the treatment of muscular
10 dystrophies, a heterogeneous group of severe degenerative diseases of the muscle caused by mutations in the genes encoding for the membrane-associated protein dystrophin or for other members of the dystrophin-associated protein complex connecting the muscle fiber cytoskeleton with the extracellular matrix.

15 Until now, the attempts to correct muscular dystrophy with gene therapy based on the implantation of muscles or other tissues stem cells, have been thwarted by enormous difficulties in the isolation of a suitable number of myogenic cells to be genetically-modified or to the poor yield of phenotypic conversion. By way of example, the difficulty in obtaining
20 a reasonable number of satellite cells to be genetically-modified is a limit to gene therapy of patients with Duchenne muscular dystrophy or with Becker muscular dystrophy (Salvatori, G., et al., 1993; Webster, C. et al., 1990). Further problems related to the implantation of genetically-modified cells in dystrophic patients are the immunogenicity of viral

vectors, the difficulty in developing an effective administration route and the poor survival of injected cells. Furthermore, the expression of dystrophin itself has been reported to induce cellular and/or humoral immune responses in dystrophin-lacking patients (New England J. of Medicine 333, 732-733, 1995).

It has been known for some time that forced expression of MyoD, and related members of the myogenic family of basic helix-loop-helix transcription factors, would activate myogenesis in non-muscle cells (Davis, R. L., et al., 1987; Cossu, G., et al., 1996; Cossu, G., 1997). The Applicant itself has recently reported that fibroblasts undergo myogenic differentiation when co-cultured with myogenic lines (C2C12) or primary cells, but not with other cell types (Breton, M. et al., 1995; Gibson, A.J., et al., 1995; Salvatori, G. et al., 1995). WO 95/12979 discloses a general method for inducing cell differentiation to a novel phenotype, for example muscular phenotype, by inserting the genic sequences of factors such as MyoD, myogenin, Myf-5 and MRF4 into the cells. The same document neither considers any possibility to convert genetically-modified cells to the myogenic phenotype in order to make them suitable for gene therapy, nor envisages the possibility to carry out an "ex vivo" myogenic conversion.

GB 2293604 discloses the use of fibroblasts in the treatment of muscular pathologies, wherein fibroblasts themselves can be transformed with a therapeutically active gene, for example the dystrophin gene, whereas the possibility to induce differentiation by means of myogenic factors has not been considered.

In light of what stated above, it appears remarkably advantageous to rely on a method which allows a high number of cells to be converted

to the myogenic phenotype, after being genetically-modified ex-vivo, in order to correct a genetic defect, such as muscular dystrophy, or any other dysfunction related, for instance, to insufficient or incorrect production of a protein or a plasma factor or other secreted or circulating proteins, as in
5 the case of diabetes, hemophilia, pituitary dwarfism.

It has now been found that it is possible to convert genetically-modified fibroblasts to the muscular phenotype, with a high-efficiency process, so as to effectively produce therapeutical proteins or proteins able to correct the genetic defects, particularly muscular dystrophy.

10 According to a first aspect, the invention provides a high-efficiency method for the preparation of genetically-modified fibroblasts expressing muscle lineage commitment genes, which comprises:

- a) ex-vivo transduction of fibroblasts with a therapeutic gene or a gene capable of correcting a genetic defect;
- 15 b) transient expression of the muscle lineage commitment gene in fibroblasts transduced as at point (a), through transformation of the cells with a high efficiency DNA transfer method, preferably a viral vector, more preferably selected from baculovirus, adeno-associated viruses and, most preferably, adenovirus, or with other
20 high efficiency DNA transfer means, such as liposomes, nucleoprotein complexes, polyethylenimines, wherein the gene of the muscle lineage commitment is under the control of a strong promoter, preferably a viral promoter.

"Muscle lineage commitment gene" means any gene capable of
25 converting fibroblasts to the myogenic phenotype, particularly MyF-5, MRF4, myogenin and, preferably, MyoD genes.

Therapeutical genes which can be transduced into fibroblasts

before the myogenic conversion are, for example, genes involved the various types of muscle dystrophies, such as sarcoglycan, emerin and, preferably, dystrophin genes, or genes coding for circulating plasma proteins, such as coagulation factors or insulin, for hormones, such as growth hormone, or other genes, such as hypoxanthine-guanine phospho-
5 ribosyl transferase, adenosine deaminase, purine nucleoside phospho-
rylase, glucocerebrosidase, low density lipoprotein receptor, phenyla-
lanine hydroxylase, arginine succinate synthetase and aryl-sulfatase.

A second aspect of the invention relates to genetically-modified
10 fibroblasts, transiently expressing a gene of the muscle lineage
commitment, preferably MyoD, obtained by the method of the invention.

The conversion of fibroblasts to the myogenic phenotype by
transient expression of a muscle lineage commitment gene, proved to be
surprisingly more effective than other alternative techniques. In fact, co-
15 culture of fibroblasts with satellite cells, treatment with dexamethasone
and transfection with calcium phosphnate, lipofectamine, or
electroporation of the same plasmid expressing MyoD, induced myogenic
conversion in a percentage ranging from 1% to 14%, in comparison with
values higher than 70% in case of infection with a recombinant adenoviral
20 vector. Furthermore, the efficiency of conversion was found to increase
linearly for m.o.i. ("multiplicity of infection") values from 500 to 2000,
whereas cytotoxicity at maximum m.o.i. values, remained within
acceptable limits. Similar results were obtained with human or murine
fibroblasts, whereas as far as tissutal fibroblasts are concerned, dermal
25 fibroblasts gave better results. One main advantage of the method of the
invention is that transient expression of the exogenous muscle lineage-
commitment gene activates the corresponding endogenous gene, therefore

irreversibly committing cells to myogenesis, thus rendering constitutive expression of the transgene unnecessary. The actual myogenic conversion of fibroblasts transiently expressing exogenous MyoD has been confirmed by immuno-histochemistry, electron microscopy and gene expression
5 analysis of different muscle-specific markers, such as myosin light and heavy chains, acetylcholine receptor α -subunit, M creatine kinase, myogenin and MyoD.

The high efficiency of the method allows the preparation of genetically manipulated fibroblasts in which a therapeutic gene, or a gene
10 correcting the genetic defect in the muscle has been inserted, which may be stably converted to the myogenic phenotype. In fact, conversion to the muscle phenotype prevents cell replication and provides stable implants, based on the use of muscle fibers.

Furthermore, the efficiency of the method as well as the stability of
15 the resulting product allow to successfully carry out gene-therapy, in which genetically-modified fibroblasts expressing a gene of the muscle lineage commitment, after appropriate ex-vivo treatment, are injected into muscle tissue where they are capable of regenerating the muscle fibers and express the correct gene.

20 A number of evidences proved that fibroblasts treated ex-vivo as herein disclosed are able to regenerate muscle fibers in mice, indistinguishable from those originating from primary myogenic (satellite) cells, with a long-lasting effect. Moreover, after treatment, only antibody mediated immune response against proteins of adenoviral
25 infected fibroblasts has been detected. No cell-mediated immune response has been observed at the site of injection of the modified fibroblasts. This is a significant advantage in gene therapy, as one of the major problems

associated to the in vivo use of adenoviral vectors is the induction of significant, T-cell-mediated immune responses against both the viral and transgenic proteins.

According to a further aspect, the invention relates to the use of
5 fibroblasts obtained by the above described method, for "ex vivo" gene therapy or for the preparation of compositions for stable cell implants based on muscle fibers.

A typical application of the ex-vivo gene therapy comprises, for example, isolating dermal fibroblasts from a patient suffering from a
10 genetic disease which alters the muscle structure or functionality, such as dystrophy, expanding the cultured cells, transducing the cells ex-vivo with a retroviral vector containing the correct gene, and inducing myogenesis by infection with an adenoviral vector, or with another vector as mentioned above, containing the gene of the muscle lineage
15 commitment, and re-implanting modified cells into the muscle tissue.

Another typical approach for the preparation of cell implants based on muscle fibers comprises isolating dermal fibroblasts from a patient suffering from a disease characterised by, for example, lack of a plasma protein (such as diabetes, pituitary dwarfism, hemophilia), expanding the
20 cultured cells, transducing the cells ex-vivo with a retroviral vector containing the therapeutic gene, and inducing myogenesis by infection with an adenoviral vector, or with another vector as mentioned above, containing the muscle lineage commitment gene, encapsulating the modified cells in the most suitable implantation matrix and implanting the
25 preparation in the preferred body site. In this specific application, induction of myogenesis and subsequent differentiation into muscle tissue is not aimed at the restoration of muscle functionality, but to the stability

of the implant by arrest of cell division.

As further applications of the present invention, its use in zootechnic field can be envisaged, to induce a specific characteristic in animals, for example an increase in weight, by production of a hormone
5 or any other substance by the cells treated ex vivo with the herein disclosed method and then re-implanted into the animal; or the creation or use of animal models of human pathologies for the study of novel therapeutical procedures to be carried out with the method of the invention.

10 The following examples illustrate the invention in greater details.

Example 1

Preparation of genetically-modified fibroblasts expressing MyoD.

Fetal fibroblasts were isolated from skin and skeletal muscle of C3H mouse embryos (15-17 days) or legally aborted human fetuses (8-12
15 weeks) as described in Salvatori et al., *Human Gene Ther.*, 1993, 4:713-723, or human dermal or muscle fibroblasts were obtained from tissues of patients undergoing post-traumatic surgery. In this case tissues were finely minced with scissors, digested with 2 mg/ml dispase, 0.1 mg/ml collagenase in phosphate buffered saline (PBS) for 45' at 37°C, washed in
20 RPMI medium, and pipetted to obtain a single-cell suspension.

Murine bone marrow fibroblasts transgenic for the lacZ gene with nuclear localization, were obtained by resuspending and plating cells flushed from the long bones of 8-10-wk-old MLC3F/nlacZ mice. Human bone marrow fibroblasts were obtained from healthy donors after removal
25 of non-adherent cells. All cells were grown in RPMI supplemented with 15% Fetal calf serum (FCS), 1% gentamycin and 0.3 mM β -mercaptoethanol (growth medium). Human bone marrow fibroblasts were

supplemented with 2 ng/ml bFGF.

Myogenic differentiation was induced by shifting the cells to RPMI supplemented with 2% horse serum (differentiation medium). Fibroblasts were purified by sub-culture (at least two rounds) in growth medium.

5 Removal of myogenic cells was routinely verified by immunocytochemical staining of a cell aliquot sub-cultured for 5 days in differentiation medium.

For transduction, fibroblasts (from third to tenth passage) were infected with a replication-defective retroviral vector (LBSN) expressing
10 a cytoplasmic β -galactosidase gene under the LTR promoter as described (Salvatori, G., et al., 1993).

For the subsequent step (transient expression of MyoD), cells were treated with the Ad5-derived, E1A-deleted adenoviral vector expressing the full-length murine MyoD c-DNA under the transcriptional control of
15 Rous Sarcoma Virus (RSV) LTR (Murry, C. E., et al., 1996). In some control experiments, cells were transfected by standard precipitation techniques with calcium-phosphate or lipofectamine (Dotap) with 10 μ g of the PMC11 plasmid, containing the MyoD cDNA under the control of the CMV promoter.

20 Alternatively, cells were electroporated with 6 μ g of the same plasmid in growth medium at 120 V, 960 mF. After transduction, cells were grown for 24 hrs in growth medium and then either shifted to differentiation medium for 3-4 days or injected in vivo.

In some experiments, cells were pre-labelled with 0.5 mCi/ml of
25 [14C] thymidine (Amersham) for 24 h and then exposed to the adenoviral vector expressing MyoD and survival was measured by counting residual cpm incorporated.

Example 2

Implantation of MyoD-converted fibroblasts into mouse muscles.

1 or 2 millions of transduced (or transgenic) human or murine fibroblasts, converted by transient expression of MyoD, were trypsinized, resuspended in 20-50 μ l of PBS and injected into a single site of the regenerating tibialis anterior muscle of either syngeneic (C3H) or immunodeficient (scid/bg) mice which had received a 30- μ l injection of 10⁻⁵ M cardiotoxin (Latoxin) 48 hrs earlier.

For some experiments, myogenically converted mouse fibroblasts were labelled with DiI dye 1 hr before injection in vivo (a 0.5% solution of DiI in absolute ethanol was diluted just before use in 0.3 M sucrose to a final concentration of 0.05%).

Mice were sacrificed after various periods of time, and muscles were cryo-sectioned and stained for β -galactosidase activity or processed for immuno-histochemistry. At the time of sacrifice, serum was collected from C3H mice and reacted with adeno-infected or control cells at various dilutions, followed by a fluorescein-conjugated anti-mouse IgG secondary antibody.

Example 3

Immunocytochemistry, electron microscopy and RNA analysis techniques.

Immunofluorescence analysis was carried out as described (Cusella - De Angelis, M.G., et al., 1994) using the following antibodies: MF20, a monoclonal antibody which recognises all sarcomeric myosins (Bader, D., et al., 1982); a rabbit antiserum against sarcomeric proteins (Tajbakhsh, S., et al., 1994); an anti-MyoD polyclonal antibody (Hasty, P., et al., 1993); BD5, a monoclonal antibody which recognises slow myosin heavy

chains (Yasin, R., et al., 1977); a rabbit polyclonal antibody against human fetal myosin (Edom, F., et al., 1994); an anti-bromo-deoxyuridine (BrdU) monoclonal antibody; anti-leu, anti-CD4 and anti-Mac3 rat anti-mouse leukocyte antigen antibodies. Briefly, cells cultures or cryostat
5 sections were fixed with 4% paraformaldehyde for 10 min at 4°C, washed 3X in PBS, and incubated at 4°C with the primary antibodies in PBS + 1% bovine serum albumin (BSA). BrdU labelled cell-cultures were treated for 10 min at rt with 2M HCl and washed 3X with PBS before incubation with the anti-BrdU antibody.

10 After the first incubation, cells or sections were washed 3X with PBS + 1% BSA and incubated for 1 hr at rt with rhodamine-conjugated goat anti-mouse Ig or with a fluorescein-conjugated goat anti rabbit Ig (1:100 dilution).

Cultures or sections were then washed, mounted in 75%
15 glycerol/PBS (pH 7.5), and observed under a Zeiss Axiophot epifluorescence microscope.

For electron microscopy cells were washed in PBS, fixed in 2% glutaraldehyde in 0.1 M Millonig's buffer (pH 7.4) for 1 hr at 4°C, post-fixed for 1 hr in 1% buffered osmium tetroxide and dehydrated in graded
20 alcohol. Cells were treated with propylene oxide, embedded in Epon 812 and cut into ultrathin sections. The ultrathin sections were stained with uranyl acetate and lead citrate, and examined with a Zeiss 109 electron microscope.

For RNA analysis, RNA was extracted by the method of
25 Chomczynski et al. (Chomczynski, P., et al., 1987), run in 15 µg aliquots on 1% agarose/formaldehyde gels, and transferred by capillary Northern blotting to nylon membranes (Amersham Hybond-N).

Filters were cross-linked for 2 hrs at 80 °C under vacuum, and hybridized to [32P]-labelled probes for MyoD and myogenin (Bober, E., et al., 1991), MLC1F and MCK (Lyons, G. E., et al., 1991), Ach-receptor α -subunit (25) under standard conditions (26).

5 - **Example 4**

Analysis of in vitro converted fibroblasts expressing the myogenic phenotype.

In order to compare the adeno-MyoD-induced phenotype with that of primary myogenic cells, a number of muscle-specific markers were analysed by immuno-cytochemistry, electron microscopy and gene expression analysis, in human and murine converted dermal fibroblasts, and in differentiating satellite cells of comparable age.

All differentiated myotubes derived from fusion of converted murine newborn dermal fibroblasts express fast embryonic myosin heavy chains, while a fraction of them also express slow myosin heavy chains, while a fraction of them also express slow myosin heavy chains, as observed in myotubes derived from satellite cells.

Similarly, myotubes derived from human fetal dermal fibroblasts show a well organized initial sarcomerogenesis, with aligned sarcomeres and patterned Z lines, as reported for myotubes derived from primary myogenic cells, which never complete sarcomerogenesis in vitro.

In order to verify whether the introduction of MyoD in primary fibroblasts would also activate transcription of genes responsible for membrane and metabolic muscle-specific functions, the Applicant measured by Northern blotting the expression of RNAs coding muscle-specific proteins such as the acetylcholine (ACh) receptor α -subunit, M creatine kinase (MCK), as well as MyoD, myogenin, and myosin light

chain 1 fast (MLC1F) chosen as positive controls.

No detectable level of any of these messages was detected in unconverted fibroblasts; on the other hand, these mRNAs were expressed at comparable levels in myotubes derived from converted fibroblasts and in myotubes derived from satellite cells of corresponding age.

Thus, under all the parameters analysed in vitro, myotubes originating from converted fibroblasts cannot be distinguished from those derived by primary myogenic cells.

Afterwards, the Applicant investigated whether fibroblasts exposed to the MyoD adenoviral vector would still maintain the capacity to divide, since MyoD overexpression has an anti-proliferative effect. Murine and human fetal skin fibroblasts were infected with the MyoD adenoviral vector for 3 hrs at an m.o.i. of 2,000 in serum-free medium, cultured for 12 hrs in growth medium containing 10 mM BrdU, fixed at 12, 24, 48 and 72 hrs after infection, and double-stained with anti-MyoD and anti-BrdU antibodies.

24 hrs after exposure to the adenoviral vector, only a few cells expressing MyoD had incorporated BrdU, while no double-positive cells were detected at 48 and 72 hrs. Expression of MyoD therefore blocks cell division in converted fibroblasts.

Example 5

Myogenic conversion efficiency of human and murine fibroblasts of different origins

Fibroblasts were isolated, expanded, infected with the MyoD adenoviral vector for 3 hrs at an m.o.i. of 2,000, cultured for a further 24 hrs and then induced to differentiation as described. Table 1 shows the conversion % values.

The conversion efficiency was measured as percentage of cells which expressed sarcomeric myosin heavy chains, as shown by staining with anti-myosin antibody. (MF20). Values shown are the average of two separate experiments, each performed in triplicate.

Table 1

		Murine		Human	
		Fetal	Adult	Fetal	Adult
10	Derma	70	56	65	42
	Muscle	43	44	40	32
	Bone marrow	ND	6	ND	6

ND: not done.

Example 6

Survival of MyoD-converted fibroblasts and satellite cells (from MLC3F/LacZ mice) after injection into regenerating Tibialis Anterior muscle (TA) of SCID/bg mice.

20 μ l containing 1×10^6 cells were injected into a single site of regenerating TA of SCID/bg mice.

At the indicated times, mice were sacrificed and successive 15 μ m cryostat sections were prepared from the TA muscle. 1 every 5 slides was X-gal stained. Nuclei were counter-stained with Hoechst. The X-gal stained sections, were scored for the number of β -gal⁺ nuclei and the obtained values were multiplied x 5 (total No. of nuclei). In addition β -gal⁺/total nuclei in 200 μ^2 areas was counted. Results are reported in Table 2. Note that the increase in the β -gal⁺/total nuclei ratio is due to the

decrease in mononucleated cells which progressively occurs during muscle regeneration (fusion).

Table 2

No. of β -gal ⁺ nuclei/muscle (0% of injected cells)		No. of β -gal ⁺ nuclei/injection site (200 μ^2) (0% of donor nuclei)	
Time(weeks)	MyoD	satellite cells	MyoD
	fibroblasts		fibroblasts
0	1.0x10 ⁶ (100)	1.0x10 ⁶ (100)	
1	2.1x10 ³ (0.2)	0.5x10 ³ (0.05)	8/242 (3.3)
2	1.8x10 ³ (0.18)	1.9x10 ³ (0.19)	7/127 (5.5)
4	1.6x10 ³ (0.16)	3.3x10 ³ (0.33)	6/99 (6.0)
8	1.9x10 ³ (0.19)	3.6x10 ³ (0.36)	7/56 (12.5)
			2/256 (0.8)
			6/123 (4.8)
			8/105 (8.5)
			12/60 (13.1)

Example 7**Muscle regeneration by genetically-modified fibroblasts expressing MyoD**

Fibroblasts isolated from human fetal skin were expanded and
5 transduced in vitro with a high-titer stock of the retroviral vector LBSN,
carrying a lacZ gene encoding a cytoplasmic form of β -galactosidase
(Salvatori, G., et al., 1993).

Transduction efficiency, estimated by the number of β -gal-staining
cells in culture, ranged between 40 and 70%, making further selection of
10 the transduced cells (e.g., G418 resistance) unnecessary. Transduced
fibroblasts were exposed to the adeno-MyoD vector at an m.o.i. of 2,000,
and then injected into the regenerating TA muscles of scid/bg mice (106
cells/muscle in a single injection).

The efficiency of myogenic conversion of transduced fibroblasts
15 was checked by allowing part of the cell culture to differentiate in vitro.
On average, about 70% of the fibroblasts underwent myogenic conversion
in these conditions, and most myotubes (> 90 %) scored positive for
cytoplasmic β -gal expression. After 1, 2 and 4 weeks, mice were
sacrificed and the TA serially sectioned and tibialis anterior muscles were
20 cut and stained for β -gal activity.

Two weeks after injection, β -gal+ fibers were observed in 7 out of
8 injected muscles. Higher magnification clearly revealed fibers
accumulating the reporter gene product at variable levels, suggesting a
variability in the proportion of injected/host cells in the β -gal+ fibers.

25 The presence and contribution of human cells in the newly formed
fibers was confirmed by immunocytochemical analysis using an antibody
which recognizes human but not mouse fetal myosin heavy chains, which

showed patches of intensive expression of human muscle-specific proteins in the regenerating areas.

In general, the average number of β -gal+ fibers per muscle obtained by injecting human converted fibroblasts was lower than that observed after injection of murine fibroblasts, although comparable to the number of positive cells observed in experiments in which lacZ-transduced human satellite cells were used. This indicates that human cells are, as expected, less efficient than murine ones in colonizing a mouse muscle.

However, and more importantly, human converted fibroblasts perform like primary myogenic cells in vivo, in terms of both number and size of newly formed fibers.

In order to better quantify the survival of human myogenically converted fibroblasts in mouse muscle, the Applicant also performed dot-blot Southern analysis with an Alu probe, as previously described (Salvatori, G., et al., 1993). To this purpose DNA was extracted from TA muscles of scid/bg mice two weeks after the injection of MyoD-converted human fibroblasts (following the same experimental protocol described above). As a positive control, the same number of human satellite cells was injected in similarly treated contra-lateral TA muscles.

The results of the dot-blot indicated that approximately 0.1% of the DNA extracted from TA injected with converted fibroblasts was of human origin; on the other hand this value raised to 0.3% in the case of the sample injected with human satellite cells.

Because histochemical analysis had revealed that virtually all the β -galactosidase staining was inside muscle fibers, we can conclude that the observed values faithfully reflect the percentage of human nuclei

incorporated into regenerated muscle fibers.

Example 8

Immune response against cells exposed ex vivo to the adenoviral vector.

5 One of the major problems associated to the in vivo use of adenoviral vectors in immunocompetent recipients is the induction of a significant, T-cell-mediated immune response against both the viral proteins and the product of the transgene(s). In the model described herein, no viral particle is injected directly in vivo. However, injected
10 cells had been exposed shortly before administration to the adenoviral vector in vitro.

Replication-defective adenoviral DNA is expected to be rapidly diluted, and eventually lost, in cells in active cell division. Expression of the MyoD transgene, however, blocks almost immediately cell division in
15 the converted fibroblasts, thus preventing the possibility of diluting the adenoviral vector by continuous culture.

To test whether an immune response could be raised by cells expressing a defective adenoviral genome in vivo, the Applicant injected 2×10^6 C3H murine skin fibroblasts converted to myogenesis by
20 exposure to the adeno-MyoD vector in the regenerating muscle of singeneic mice.

Cells were labelled with DiI before injection and not with a lacZ transgene to avoid a possible immune reaction against the β -galactosidase protein. Animals were sacrificed 7, 14 and 21 days after the injection, and
25 muscles analysed for the presence of immune infiltrate by immunofluorescence using antibodies against cell surface markers of murine leukocytes and macrophages.

No significant immune infiltrate was detected for up to 3 weeks after injection around the labelled cells, even though by this time all treated mice had developed antibodies against Ad5 proteins, which recognise adeno-infected but not control C3H fibroblasts

5 These experiments indicate that fibroblasts converted in vitro by exposure to an adeno-MyoD vector, and administered in vivo by intramuscular injection, do not elicit, and are therefore unlikely to be eliminated by, a cell-mediated cytotoxic immune response.

10 In contrast, direct injection of Adenoviral vector into regenerating muscle induced a strong immune infiltrate, as already reported (Yang, Y., et al., 1996).

BIBLIOGRAPHY

- Salvatori, G., G. Ferrari, A. Mezzogiorno, S. Serivdei, M. Coletta, P. Tonali, R. Giavazzi, G. Cossu, and F. Mavilio. 1993. Retroviral vector-mediated gene transfer into human primary myogenic cells leads to expression in muscle fibers in vivo. *Human Gene Ther.* 4:713-723.
- Webster, C. e, H.M. Blau 1990. Accelerated age-related decline in replicative life span of Duchenne muscular dystrophy myoblasts: implication for cell and gene therapy. *Somatic Cell Mol. Genet.* 16:557-565.
- 10 Davis, R. L., H. Weintraub, and A.B. Lassar. 1987. Expression of a single transfected cDNA converts fibroblasts to myoblasts. *Cell* 51:987-1000.
- Cossu, G., S. Tajbakhsh, and M. Buckingham. 1996. Myogenic specification in mammals. *Trends Genet.* 12:218-223.
- 15 Cossu, G. 1997. Unorthodox myogenesis: possible developmental significance and implications for tissue histogenesis and regeneration. *Histol. Histopathol.* 12:755-760.
- Breton, M., Z., Li, D. Paulin, J.A. Harris, F. Rieger, M. Pincon-Raymond, and L. Garcia. 1995. Myotube driven myogenic recruitment of cells during in vitro myogenesis. *Develop. Dynam.* 202:126-136.
- 20 Gibson, A.J., J. Karasinski, J. Relvas, J. Moss, T.G. Sherratt, P.N. Strong, and D.J. Watt. 1995. Dermal fibroblasts convert to a myogenic lineage in mdx mouse muscle. *J. Cell Science* 108:207-214.
- Salvatori, G., L. Lattanzi, M. Coletta, S. Aguanno, E. Vivarelli, R. Kelly, G. Ferrari, J. A. Harris, F. Mavilio, M. Molinaro, and G. Cossu. 1995. Myogenic conversion of mammalian fibroblasts induced by differentiating muscle cells. *J. Cell Science* 108:2733-2739.
- 25

Murry, C. E., M. A. Kay, T. Bartosek, S. D. Hauschka, and S. M. Schwartz. 1996. Muscle differentiation during repair of myocardial necrosis in rats via gene transfer with MyoD. *J. Clin. Invest.* 98:2209-2217.

5 Cusella - De Angelis, M.G., S. Molinari, A. Ledonne, M. Coletta, E. Vivarelli, M. Bouchè, M. Molinaro, S. Ferrari, and G. Cossu, 1994. Differential response of embryonic and fetal myoblasts to TGF β : a possible regulatory mechanism of skeletal muscle histogenesis. *Development* 120:925-933.

10 Bader, D., T. Masaki, and D. A. Fischman. 1982. Immunochemical analysis of myosin heavy chain during avian myogenesis in vivo and in vitro. *J. Cell Biol.* 95:763-770.

Hasty, P., A. Bradley, J. H. Morris, D. G. Edmondson, J. M. Venuti, E. N. Olson, and W. H. Klein. 1993. Muscle deficiency and
15 neonatal death in mice with a targeted mutation in the myogenin gene. *Nature* 375:787-790.

Edom, F., V. Mouly, J. P. Babert, M. Y. Fiszman, and G. S. Butler-Browne. 1994. Clones of human satellite cells can express in vitro both fast and slow myosin heavy chains. *Develop. Biology* 164:219-229.

20 Yasin, R., K. C. Van Beers, C. E. Nurse, S. Al-Ani, D. N. Landon, and E. J. Thompson. 1977. A quantitative technique for growing human adult skeletal muscle in culture starting from mononucleated cells. *J. Neurol. Sci.* 32:347-360.

Chomczynski, P., and N. Sacchi. 1987. Single-step method of RNA
25 isolation by acid guanidinium thiocyanate-phenol-chlorophorm extraction. *Anal. Biochem.* 162:156-159.

Bober, E., G.E. Lyons, T. Braun, G. Cossu, M. Buckingham, and

H.H. Arnold. 1991. The muscle regulatory gene Myf-6 has a biphasic pattern of expression during early mouse development. *J. Cell Biol.* 113:1255-1265.

Boulter, J., W. Luyten, K. Evans, P. Mason, M. Ballivet, D. Goldman, D. Stengelin, S. Martin, S. Heinemann, and J. Patric, 1985. Isolation of a clone coding for the α -subunit of a mouse acetylcholine receptor. *J. Neurosci.* 5:2545-2552.

Sambrook, J., E. F. Fritsch, and T. Maniatis. 1989. *Molecular cloning: a laboratory manual*. 2nd ed., Cold Spring Harbor Laboratory Press, New York.

Yang, Y., S. E. Haecker, Q. Su, and J. Wilson, 1996. Immunology of gene therapy with adenoviral vectors. *Hum. Mol. Genet.* 5:1703-1712.

Tajbakhsh, S., E. Vivarelli, M. G. Cusella-De Angelis, D. Rocancourt, M. Buckingham, and G. Cossu 1994. A population of myogenic cells derived from the mouse neural tube. *Neuron* 13:813-821.

Lyons, G. E., S. Muhlebach, A. Moser, R., Masood, B. M. Paterson, M. Buckingham, and J. C. Perriard. 1991. Development regulation of creatin kinase gene expression by myogenic factors in embryonic mouse and chick skeletal muscle. *Development* 113:1017-1029.

CLAIMS

1. A method for the preparation of genetically-modified fibroblasts expressing a muscle lineage commitment gene, which comprises:

- 5 a) ex-vivo transduction of fibroblasts with a therapeutic gene or a gene capable of correcting a gene defect;
- b) transient expression of the muscle lineage commitment gene in fibroblasts transduced as at point (a), through transformation of the cells with a high-efficiency DNA transfer method, wherein the muscle
- 10 lineage commitment gene is under the control of a strong promoter.

2. A method according to claim 1, wherein the therapeutical gene is the dystrophin gene.

3. A method according to claim 1, wherein the high-efficiency DNA transfer method is a viral vector.

15 4. A method according to claim 3, wherein said viral vector is selected from baculovirus, adeno-related viruses, adeno-virus.

5. A method according to claim 3, wherein said vector is an adenovirus.

6. A method according to claim 1, wherein the muscle lineage commitment gene is selected from MyoD, Myf-5, MRF4 and myogenin.

20 7. A method according to claim 6, wherein said gene is MyoD.

8. A method according to claim 1, wherein the muscle lineage commitment gene is under the control of a viral promoter.

9. Genetically-modified fibroblasts obtainable by the method of claims 1-8.

25 10. Fibroblasts according to claim 9, wherein the muscle lineage commitment gene is MyoD.

Case No. _____

Nixon & Vanderhye P.C. (12/97)

RULE 63 (37 C.F.R. 1.63)
DECLARATION AND POWER OF ATTORNEY
FOR PATENT APPLICATION
IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

As a below named inventor, I hereby declare that my residence, post office address and citizenship are as stated below next to my name, and I believe I am the original, first and sole inventor (if only one name is listed below) or an original, first and joint inventor (if plural names are listed below) of the subject matter which is claimed and for which a patent is sought on the invention entitled:

Genetically-modified fibroblasts and the use thereof

the specification of which (check applicable box(es)):

☐ is attached hereto

☐ was filed on _____

as U.S. Application Serial No. _____

☒ was filed as PCT International application No. _____

PCT/EP99/03075

on **05-05-1999**

and (if applicable to U.S. or PCT application) was amended on _____

I hereby state that I have reviewed and understand the contents of the above identified specification, including the claims, as amended by any amendment referred to above. I acknowledge the duty to disclose information which is material to the patentability of this application in accordance with 37 C.F.R. 1.56. I hereby claim foreign priority benefits under 35 U.S.C. 119/365 of any foreign application(s) for patent or inventor's certificate listed below and have also identified below any foreign application for patent or inventor's certificate having a filing date before that of the application on which priority is claimed or, if no priority is claimed, before the filing date of this application:

Priority Foreign Application(s):

Application Number

Country

Day/Month/Year Filed

MI98A001004

Italy

08-05-1998

I hereby claim the benefit under 35 U.S.C. §119(e) of any United States provisional application(s) listed below.

Application Number

Date/Month/Year Filed

I hereby claim the benefit under 35 U.S.C. 120/365 of all prior United States and PCT international applications listed above or below and, insofar as the subject matter of each of the claims of this application is not disclosed in such prior applications in the manner provided by the first paragraph of 35 U.S.C. 112, I acknowledge the duty to disclose material information as defined in 37 C.F.R. 1.56 which occurred between the filing date of the prior applications and the national or PCT international filing date of this application:

Prior U.S./PCT Application(s):

Application Serial No.

Day/Month/Year Filed

Status: patented
pending, abandoned

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issued thereon. And on behalf of the owner(s) hereof, I hereby appoint **NIXON & VANDERHYE P.C., 1100 North Glebe Rd., 8th Floor, Arlington, VA 22201-4714, telephone number (703) 816-4000 (to whom all communications are to be directed)**, and the following attorneys thereof (of the same address) individually and collectively owner's/owners' attorneys to prosecute this application and to transact all business in the Patent and Trademark Office connected therewith and with the resulting patent: Arthur R. Crawford, 25327; Larry S. Nixon, 25640; Robert A. Vanderhye, 27076; James T. Hosmer, 30184; Robert W. Faris, 31352; Richard G. Besha, 22770; Mark E. Nusbaum, 32348; Michael J. Keenan, 32106; Bryan H. Davidson, 30251; Stanley C. Spooner, 27393; Leonard C. Mitchard, 29009; Duane M. Byers, 33363; Jeffrey H. Nelson, 30481; John R. Lastova, 33149; H. Warren Burnam, Jr. 29366; Thomas E. Byrne, 32205; Mary J. Wilson, 32955; J. Scott Davidson, 33489; Alan M. Kagen, 36178; Robert A. Molan, 29834; B. J. Sadoff, 36663; James D. Berquist, 34776; Updeep S. Gill, 37334; Michael J. Shea, 34725; Donald L. Jackson, 41090; Michelle N. Lester, 32331; Frank P. Presta, 19828; Joseph S. Presta, 35329; Joseph A. Rhoa, 37515. I also authorize Nixon & Vanderhye to delete any attorney names/numbers no longer with the firm and to act and rely solely on instructions directly communicated from the person, assignee, attorney, firm, or other organization sending instructions to Nixon & Vanderhye on behalf of the owner(s).

1. Inventor's Signature: *Fulvio MAVILIO* Date: 13-10-2000
Inventor: Fulvio MAVILIO
(first) MI (last) Italian
(citizenship)

Residence: (city) Milano (state/country) Italy
Post Office Address: Via Olgettina, 58 - Milano, Italy
(Zip Code) 20132

2. Inventor's Signature: _____ Date: _____
Inventor: _____
(first) MI (last) (citizenship)

Residence: (city) _____ (state/country) _____
Post Office Address: _____
(Zip Code) _____

3. Inventor's Signature: _____ Date: _____
Inventor: _____
(first) MI (last) (citizenship)

Residence: (city) _____ (state/country) _____
Post Office Address: _____
(Zip Code) _____

FOR ADDITIONAL INVENTORS, check box ☐ and attach sheet with same information and signature and date for each.

268050